A recent study on trastuzumab deruxtecan has shown that it preserves health-related quality of life and neurological stability in HER2+ metastatic breast cancer patients. This finding is significant, as brain metastasis status was not a factor in the preserved outcomes.
Meanwhile, other breakthroughs include Zongertinib elicitting durable responses in pretreated advanced HER2-mutant non-small cell lung cancer (NSCLC). Lenvatinib also shows efficacy in advanced hepatocellular carcinoma post-progression on atezolizumab/Bevacizumab.
In a separate study, Sacituzumab Govitecan did not significantly improve overall survival in pretreated urothelial carcinoma. Active monitoring is shown to be noninferior to guideline-concordant care in low-risk ductal carcinoma in situ (DCIS).
Additionally, the addition of Dostarlimab to chemo and Niraparib maintenance boosts progression-free survival in advanced ovarian cancer. Venetoclax plus PegC may also overcome resistance to prior BCL-2 inhibitors in relapsed/refractory acute myeloid leukemia.
The FDA has granted accelerated approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ metastatic colorectal cancer. Furthermore, filling unmet needs in Small Cell Adenocarcinoma of the Chest (SCAC) is crucial as incidence rates are rising.
Source: https://www.onclive.com/view/effects-of-trastuzumab-deruxtecan-t-dxd-on-health-related-quality-of-life-hrqol-destiny-breast12-db-12-results